WW Stock Recent News
WW LATEST HEADLINES
Oprah Winfrey left the diet company's board last year after admitting to using a weight-loss drug.
WeightWatchers is preparing to file for bankruptcy in the coming months as part of a plan to hand control of the business to its creditors, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
The wellness company faces sizable debt maturities as its business struggles
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like LTH, WW, SFM, and BYND are well-positioned to benefit.
WW International, Inc. (NASDAQ:WW ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants David Helderman - Director, Investor Relations Tara Comonte - President & Chief Executive Officer Felicia DellaFortuna - Chief Financial Officer Donna Boyer - Chief Product Officer Conference Call Participants Nathan Feather - Morgan Stanley Michael Lasser - UBS Alex Fuhrman - Craig-Hallum Capital Group Operator Good day, and welcome to the WeightWatchers Fourth Quarter and Full Year 2024 Results Conference Call. All participants will be in a listen-only mode.
WW International (WW) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.06 per share a year ago.
Fourth Quarter 2024 Financial Highlights Total End of Period Subscribers of 3.3 million, including 92 thousand End of Period Clinical Subscribers Revenues of $184.4 million; Subscription Revenues down 7.3% vs. prior year period, including Clinical Subscription Revenues of $20.5 million, up 57.9% vs.
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) will release its results for the fourth quarter and full year 2024 ended December 28, 2024, after market close on Thursday, February 27, 2025.
The Wall Street Journal reported, citing unnamed sources, that WeightWatchers and the lender advisers recently entered into a confidentiality agreement.
WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares soaring nearly 47%.